Clinuvel’s Scenesse Receives the US FDA’s Approval for Erythropoietic Protoporphyria (EPP)

 Clinuvel’s Scenesse Receives the US FDA’s Approval for Erythropoietic Protoporphyria (EPP)

Clinuvel’s Scenesse Receives the US FDA’s Approval for Erythropoietic Protoporphyria (EPP)

Shots:

  • Scenesse (afamelanotide 16mg) is a drug developed for the treatment of rare genetic metabolic disorder and is approved to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)
  • In 2018, Scenesse also received European Medicines Agency’s as an orphan medicinal product, approval for EPP and is administered as a 16mg controlled-release injectable implant, designed for up to 60 days
  • Scenesse (afamelanotide, 16mg) is a drug targeted for binding to melanocortin-1 receptor on skin cells and the results of P-III study has been published in the New England Journal of Medicine

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post